Alza Challenges Antitrust Claims In Ditropan Case

Law360, New York (June 21, 2007, 12:00 AM EDT) -- Alza Corp. has shot back at allegations raised by a purported class of indirect purchasers who claim that the Johnson & Johnson subsidiary violated federal and California antitrust laws by trying to keep generic versions of its bladder treatment Ditropan XL off the U.S. market.

Just days after Alza moved to dismiss the direct purchasers’ antitrust case against it, the Mountain View, Calif.-based company on Thursday contended that the purported class action by indirect purchasers should also be thrown out by the U.S. District Court for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.